TransMedics Group, Inc. filings document a Nasdaq-listed medical technology company built around the Organ Care System, National OCS Program and related transplant logistics services for lung, heart and liver transplantation. Its 8-K reports furnish operating results, guidance, tax valuation allowance disclosures and business drivers such as OCS case utilization, logistics revenue and aircraft assets.
Other filings cover material agreements, including headquarters facilities and completed aircraft acquisitions, as well as executive transitions, compensatory arrangements, inducement awards and proxy-governance matters. The company's disclosures also describe its common stock listing, board and shareholder voting matters, executive compensation, clinical program updates and FDA-related device disclosures.
TransMedics Group Chief Financial Officer Gerardo Hernandez reported both option exercises and share sales. On March 4, 2026, he exercised stock options that delivered 7,236 shares of common stock and, together with earlier activity, sold a total of 7,611 shares. Some of the shares were sold to satisfy tax withholding obligations tied to restricted stock unit vesting through a sell-to-cover transaction. Reported sale prices reflect a weighted average around $147.21 per share, based on multiple trades between $147.14 and $147.47. After these transactions, he directly held 14,689 TransMedics common shares.
TransMedics Group, Inc. insider Anil P. Ranganath reported an automatic sale of common stock tied to tax withholding on vested restricted stock units. On March 2, 2026, he sold 864 shares at $139.12 per share in an open-market transaction designated as a “sell to cover” for required tax obligations. After this sale, he directly held 13,091 common shares, so the transaction reflects tax-related share disposition rather than a discretionary reduction of his overall stake.
TransMedics Group executive Nicholas Corcoran reported share transactions linked to restricted stock unit vesting. On March 2, 2026, he executed an open-market sale of 2,966 shares of common stock at $139.12 per share, leaving him with 29,831 shares held directly.
Earlier, on January 23, 2026, 984 shares at $135.30 per share were disposed of to satisfy tax withholding obligations upon RSU vesting. Footnotes state both the issuer’s share withholding and the “sell to cover” sale were required to cover Corcoran’s tax liabilities tied to these equity awards.
TransMedics Group, Inc. explains how releasing a U.S. tax valuation allowance changed its previously reported fourth-quarter 2025 results. In Q4 2025 the company released a $103.3 million valuation allowance on deferred tax assets, creating a net income tax benefit of $83.8 million and driving a reported annual effective tax rate of (77.0)%.
For Q4 2025, income before income taxes was $21.6 million. Reported net income was $105.4 million, or $2.62 per diluted share. Using a 19.1% annual effective tax rate excluding the allowance release, adjusted Q4 net income is $17.5 million, or $0.47 per diluted share. The company expects future quarterly tax provisions to align more closely with typical U.S. corporate tax rates.
TransMedics Group, Inc. presents its annual report describing a fast-growing medical technology business built around its Organ Care System (OCS) and National OCS Program (NOP) for heart, lung and liver transplantation.
The company generated $605.5 million of revenue in 2025, up from $441.5 million in 2024 and $241.6 million in 2023, reflecting strong adoption of its single-use disposables and NOP services. TransMedics operates 22 fixed‑wing aircraft, is developing next‑generation and Gen‑3 OCS platforms including OCS Kidney, and is expanding logistics and R&D infrastructure in the U.S. and Europe.
The filing highlights extensive clinical evidence and a large patent portfolio but also notes risks such as fluctuating results, dependence on OCS and NOP, identified material weakness in internal controls, reimbursement dynamics, supply chain reliance, and the need for additional funding and debt service on 1.50% convertible notes due 2028.
TransMedics Group, Inc. reported strong growth for the fourth quarter and full year 2025, driven by broader use of its Organ Care System and related services. Fourth quarter revenue reached $160.8 million, up 32% year over year, while full year 2025 revenue rose to $605.5 million, a 37% increase.
Net income jumped to $105.4 million in the fourth quarter and $190.3 million for the full year, helped by a one-time tax benefit from releasing a valuation allowance on deferred tax assets. The company maintained gross margins around 58–60% and increased investment in research, clinical programs, and commercial infrastructure.
TransMedics completed 5,139 U.S. NOP cases in 2025, expanded its owned aviation fleet to 22 aircraft, and received FDA approval for key heart and lung trials. For 2026, it projects revenue between $727 million and $757 million, implying 20% to 25% growth over 2025.
TransMedics Group, Inc. Chief Commercial Officer Giovanni Cecere reported equity awards consisting of stock options and restricted stock units. He was granted options to purchase 16,734 shares of common stock at an exercise price of $0.00 per share and 11,082 restricted stock units, each representing one share of common stock.
The option award vests as to 25% of the underlying shares on February 18, 2027, with the remaining shares vesting in equal monthly installments over the following three years, subject to continued service. The RSU grant reflects additional direct equity-based compensation tied to the company’s stock.